EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza

Vanyo Mitev iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27156827 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Vanyo Mitev. Beteiligte Einrichtung: Research Institute of Innovative Medical Science, Medical University Sofia, Akad. Ivan Geshov 15, 1431 Sofia, Bulgaria. Hauptthemen laut MEDLINE: Colchicine, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Influenza, Human. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bulgarian National Science Fund, Bulgarian National Plan for Recovery and Resilience.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19) and influenza share key pathogenic mechanisms, including viral invasion, dysregulated innate immune activation, and the development of severe systemic complications. A central mediator of disease progression in both infections is the hyperactivation of the NLRP3 inflammasome, which drives excessive production of pro-inflammatory cytokines, immunothrombosis, multiorgan injury, and increased mortality. Colchicine possesses a unique pharmacokinetic property of preferential accumulation within myeloid cells, where sufficiently high intracellular concentrations inhibit NLRP3 inflammasome activation. This mechanism provides a biological rationale for preventing the cytokine storm and its downstream consequences when colchicine is administered early during infection. Available pharmacokinetic, toxicological, and clinical evidence suggests that loading doses of colchicine up to approximately 0.05 mg/kg body weight can be administered safely in appropriately selected patients, provided that clinically significant drug–drug interactions and hepatic or renal impairment are carefully excluded. The widely accepted belief that total doses of 7–7.5 mg are inherently lethal appears to reflect historical cases complicated by drug interactions and/or hepatic or renal impairment, rather than toxicity attributable to colchicine dose alone. These observations support reconsideration of current guideline recommendations regarding colchicine dosing. In particular, cumulative doses below 0.1 mg/kg appear to be consistently safe, whereas doses between 0.1 and 0.2 mg/kg are associated with only a low risk of toxicity and rarely with severe intoxication. Reassessment of colchicine dosing strategies may therefore be warranted to optimize NLRP3 inflammasome inhibition and improve outcomes in patients with COVID-19 and influenza.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColchicineNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesInfluenza, HumanHumansCOVID-19SARS-CoV-2COVID-19 Drug TreatmentAnimalsPandemicsCytokine Release Syndrome

Stichwörter der Autor:innen

COVID-19NLRP3 inflammasomecolchicinecytokine stormimmunothrombosisinfuenza

Substanzen

ColchicineNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesNLRP3 protein, human

Autor:innen und Institutionen

  • Research Institute of Innovative Medical Science, Medical University Sofia, Akad. Ivan Geshov 15, 1431 Sofia, Bulgaria.
  • Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University Sofia, Akad. Ivan Geshov 15, 1431 Sofia, Bulgaria.

ORCID-Profile: Vanyo Mitev

Förderung

  • Bulgarian National Science Fund
  • Bulgarian National Plan for Recovery and Resilience

Zitieren

APA

Mitev, V. (2026). Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27156827

Vancouver

Mitev V. Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27156827

BibTeX
@article{Mitev2026,
  author = {Mitev, Vanyo},
  title = {Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27156827}
}
Kostenlos starten →